Author:
Koyama Nobuhiro,Tomoda Hiroshi
Reference35 articles.
1. NIAID’s Tuberculosis Antimicrobial Acquisition & Coordinating Facility (TAACF). Website: http://www.Taacf.org/about-TB-background.html . Accessed 18 Jan 2010
2. O’Brien RJ (2001) Global alliance for TB drug development. Scientific blueprint for TB drug development. Tuberculosis 81:1–52
3. Iwatsuki M, Tomoda H, Uchida R, Gouda H, Hirono S, Kobayashi S, Omura S (2006) Lariatins, antimycobacterial peptides produced by Rhodococcussp. K01-B-0171, have a lasso structure. J Am Chem Soc 128:7486–7491
4. Iwatsuki M, Uchida R, Takakusagi Y, Matsumoto A, Jiang CL, Takahashi Y, Arai M, Kobayashi S, Matsumoto M, Inokoshi J, Tomoda H, Omura S (2007) Lariatins, novel anti-mycobacterial peptides with a lasso structure, produced by Rhodococcus jostiiK01-B0171. J Antibiot (Tokyo) 60:357–363
5. Iwatsuki M, Koizumi Y, Gouda H, Hirono S, Tomoda H, Omura S (2009) Lys17 in the ‘lasso’ peptide lariatin A is responsible for anti-mycobacterial activity. Bioorg Med Chem Lett 19:2888–2890